Younger age, faster diagnosis, and undergoing treatment in Europe were among the factors associated with greater likelihood of survival in cases of progressive multifocal leukoencephalopathy (PML) in multiple sclerosis patients treated with natalizumab (Tysabri), a researcher reported here.
Analysis of the first 79 cases of PML in patients receivingnatalizumab found that these were the strongest survival predictors, according to John Foley, MD, of the Rocky Mountain Multiple Sclerosis Clinic in Salt Lake City............. Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/1768